-$1.18 EPS Expected for Five Prime Therapeutics, Inc. (FPRX) This Quarter

Brokerages expect Five Prime Therapeutics, Inc. (NASDAQ:FPRX) to post ($1.18) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Five Prime Therapeutics’ earnings. The lowest EPS estimate is ($1.28) and the highest is ($0.98). Five Prime Therapeutics reported earnings of ($0.49) per share in the same quarter last year, which would suggest a negative year over year growth rate of 140.8%. The business is scheduled to announce its next earnings results on Thursday, August 3rd.

On average, analysts expect that Five Prime Therapeutics will report full-year earnings of ($4.68) per share for the current fiscal year, with EPS estimates ranging from ($4.91) to ($4.26). For the next fiscal year, analysts expect that the company will report earnings of ($4.97) per share, with EPS estimates ranging from ($6.00) to ($3.56). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings results on Thursday, May 4th. The biotechnology company reported ($1.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.25. Five Prime Therapeutics had a negative net margin of 250.98% and a negative return on equity of 21.81%. The business had revenue of $10.13 million during the quarter, compared to analysts’ expectations of $6.05 million. During the same quarter in the prior year, the firm earned ($0.49) EPS. Five Prime Therapeutics’s revenue for the quarter was up 55.8% on a year-over-year basis.

A number of research analysts have issued reports on FPRX shares. Instinet started coverage on shares of Five Prime Therapeutics in a report on Wednesday, March 1st. They issued a “buy” rating and a $94.00 target price for the company. Nomura initiated coverage on shares of Five Prime Therapeutics in a research report on Wednesday, March 1st. They issued a “buy” rating on the stock. Zacks Investment Research upgraded shares of Five Prime Therapeutics from a “hold” rating to a “buy” rating and set a $39.00 price target on the stock in a research report on Wednesday, April 26th. Jefferies Group LLC reiterated a “buy” rating and issued a $55.00 price target on shares of Five Prime Therapeutics in a research report on Thursday, June 8th. Finally, TheStreet lowered shares of Five Prime Therapeutics from a “c” rating to a “d+” rating in a research report on Monday, March 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $60.83.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/2655739/1-18-eps-expected-for-five-prime-therapeutics-inc-fprx-this-quarter.html.

Shares of Five Prime Therapeutics (FPRX) traded up 5.040% during trading on Tuesday, hitting $30.325. The company had a trading volume of 92,433 shares. The stock’s 50-day moving average is $29.90 and its 200 day moving average is $40.23. Five Prime Therapeutics has a 52-week low of $26.65 and a 52-week high of $60.98. The firm’s market capitalization is $845.98 million.

Hedge funds have recently added to or reduced their stakes in the stock. BB Biotech AG acquired a new stake in Five Prime Therapeutics during the first quarter valued at approximately $26,299,000. Renaissance Technologies LLC acquired a new stake in Five Prime Therapeutics during the first quarter valued at approximately $16,734,000. MARSHALL WACE ASIA Ltd acquired a new stake in Five Prime Therapeutics during the first quarter valued at approximately $10,272,000. Marshall Wace North America L.P. acquired a new stake in Five Prime Therapeutics during the first quarter valued at approximately $10,272,000. Finally, State Street Corp raised its stake in Five Prime Therapeutics by 25.7% in the first quarter. State Street Corp now owns 1,249,520 shares of the biotechnology company’s stock valued at $45,175,000 after buying an additional 255,488 shares in the last quarter. Institutional investors and hedge funds own 86.01% of the company’s stock.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:FPRX”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
President Trump Hurting Tourism in the U.S.
President Trump Hurting Tourism in the U.S.
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Blue Apron Filed Thursday for Public Offering
Blue Apron Filed Thursday for Public Offering
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Large Auto Lender Checked Just 8% of Incomes for Applicants
Large Auto Lender Checked Just 8% of Incomes for Applicants


Leave a Reply

© 2006-2017 Ticker Report. Google+.